drugset

drugset / Trial / NCT01271972

Study of Nesvacumab (REGN910/ SAR307746)

NCT01271972 ↗

Phase 1 Completed 53 enrolled Regeneron Pharmaceuticals Sanofi · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) administered IV every 2 weeks.

Timeline

Start: 2011-01
Primary completion: 2014-09
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	nesvacumab	Monoclonal antibody	—	Intravenous

Indications